2018 Schedule and Program for the ASH Meeting on Lymphoma Biology
The following programming corresponds to the 2018 ASH Meeting on Lymphoma Biology.
-
Thursday - August 2
2:00 p.m. - 7:00 p.m. Registration 5:00 p.m. – 5:20 p.m. Welcome, Introduction, and Announcements
Program Co-Chairs:
Riccardo Dalla-Favera, MD, Columbia University
Kojo S.J. Elenitoba-Johnson, MD, University of Pennsylvania
Freda K. Stevenson, DPhil, University of Southampton Medical School5:20 p.m. – 6:05 p.m. Opening Keynote Address
Michael Reth, PhD, University of Freiburg
B Cell Antigen Receptor Signaling of Normal and Transformed B Cells6:05 p.m. – 8:00 p.m. Welcome Reception and Exhibits -
Friday - August 3
7:00 a.m. – 5:00 p.m. Registration 7:00 a.m. – 8:00 a.m. Breakfast and Exhibits 8:00 a.m. – 10:00 a.m. The Germinal Center as the Target Site
Chair:
Riccardo Dalla-Favera, MD, Columbia University
Speakers:
Shane Crotty, PhD, La Jolla Institute for Allergy and Immunology
T Follicular Helper (Tfh) CD4 T cells, Germinal Centers, Immunodominance, and the Generation of Memory to Vaccines
David Dominguez-Sola, MD, PhD, Icahn School of Medicine at Mount Sinai
Germinal Center Dynamics in the Pathogenesis of B cell non-Hodgkin Lymphomas
Stefano Casola, MD, PhD, International Foundations of Medicine
Targeting BCR Function in Mature B-Cell Neoplasms: Opportunities, Challenges, and Warnings: Lessons From Mouse Models
Oral Abstract Presenters:
Katia Basso, PhD, Columbia University
MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis
Vipul Shukla, PhD, La Jolla Institute for Allergy and Immunology
Tet Proteins Regulate Enhancer Function and Class Switch Recombination During B Cell Activation10:00 a.m. – 10:15 a.m. Networking Coffee Break 10:15 a.m. – 12:15 p.m. Microenvironment Influences in Lymphoma
Chair:
Freda K. Stevenson, DPhil, University of Southampton Medical School
Speakers:
Hans-Guido Wendel, MD, Memorial Sloan Kettering Cancer Center
Immune Receptor Mutations in Lymphoma
Karin Tarte, PhD, INSERM U1236 & CHU Rennes
Follicular Lymphoma Cell Niche: Role and Heterogeneity of FL-CAF
Ron Levy, MD, Stanford School of Medicine
Combining Intratumoral Injections of Toll-Like Receptor Agonists With Checkpoint Antibodies
Oral Abstract Presenters:
Elena Viganò, PhD, BC Cancer Research Centre
Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition
Olga Kutovaya, PhD, BC Cancer Research Centre
UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation Through a Cyclin D1-Dependent Mechanism12:15 p.m. – 1:15 p.m. Lunch and Exhibits 1:15 p.m. – 1:45 p.m. Company Presentations (Cancelled) Free Time 1:45 p.m. – 4:00 p.m. Continuing Conversations
Moderator:
Francesco Forconi, MD, PhD
Continuing Conversation on B-Cell Receptor-Associated Kinase Inhibition in Tumor and Normal B Cells in vivo and in vitro
Moderator:
Silvia Deaglio, MD, PhD
Continuing Conversation on Chronic Lymphocytic Leukemia Microenvironment and its Relevance for Tumor Progression
Moderators:
Laura Pasqualucci, MD and Ari Melnick, MD
Continuing Conversation on Epigenetic Mechanisms in Lymphoma – What are the Biggest Unanswered Questions?
Moderator:
David Dominguez-Sola, MD, PhD
Continuing Conversation on Germinal Center Biology, Dynamics and B cell Lymphomagenesis
Moderator:
Megan Lim, MD, PhD
Continuing Conversation on Mass Spectrometry-based Proteomics in the Identification of Novel Biologic Insights in T-cell Lymphomas
Moderator:
Andreas Strasser, MSc, PhD, FAA
Continuing Conversation on the Tumor Suppressor p53 – How Does it Prevent Cancer and How Can Mutant p53 be Targeted Therapeutically?4:00 p.m. – 5:30 p.m. Poster Presentations 5:30 p.m. – 7:00 p.m. Dinner (provided) 7:00 p.m. – 9:00 p.m. Discovery of Novel Pathogenic Mechanisms and Therapies in Lymphoma
Chair:
Ari Melnick, MD, Weill Cornell Medical College
Speakers:
Ari Melnick, MD, Weill Cornell Medical College
Harnessing the Epigenome for Immunotherapy of B-cell Lymphoma
Laura Pasqualucci, MD, Columbia University
Genetic Basis of Epigenetic Dysregulation in Germinal Center-Derived Lymphomas
Suzanne Cory, PhD, Walter and Eliza Hall Institute of Medical Research
From Translocation to Therapy: How Understanding the BCL-2 Cell Life/Death Switch Is Leading to More Effective Therapy
Oral Abstract Presenter:
Justin Taylor, MD, Memorial Sloan Kettering Cancer Center
Oncogenic Mutations in XPO1 Promote Lymphoid Transformation by Altering Nuclear-Cytoplasmic Localization of NFκB Signaling Intermediates
Ryan M. Young, PhD, National Cancer Institute, National Institutes of Health
Functional Proteogenomic Screens Reveal a Myd88-TLR9 B Cell Receptor Supercomplex in Diffuse Large B-Cell Lymphoma -
Saturday - August 4
7:00 a.m. – 5:00 p.m. Registration 7:00 a.m. – 8:00 a.m. Breakfast and Exhibits 8:00 a.m. – 9:45 a.m. New Technologies and Diagnostics
Chair:
Ash A. Alizadeh, MD, PhD, Stanford University Medical Center
Speakers:
Michael Angelo, MD, PhD, Stanford University
Single Cell Analysis of Signaling
Ronald N. Germain, MD, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Single Cell Imaging
Ash A. Alizadeh, MD, PhD, Stanford University Medical Center
Circulating Tumor DNA
Oral Abstract Presenter:
Daniel J. Hodson, MD, PhD, University of Cambridge
Engineering the Genetics Events of Lymphomagenesis in Normal Human B Cells for High-Throughput, Functional Prioritization of Lymphoma Driver Genes9:45 a.m. – 10:00 a.m. Networking Coffee Break 10:00 a.m. – 12:00 noon Molecular Targeting
Chair:
Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health
Speakers:
Anthony Letai, MD, PhD, Dana-Farber Cancer Institute
Mitochondria Tell You What You Need to Know to Treat Lymphoid Cancers
Andreas Strasser, MSc, PhD, FAA, Walter and Eliza Hall Institute of Medical Research
How Does the Tumor Suppressor p53 Protect Us From Developing Cancer?
Roberto Chiarle, MD, Boston Children's Hospital
Targeted Therapy and Resistance in Lymphoma
Oral Abstract Presenters:
Guangzhen Hu, PhD, Mayo Clinic
Targetability of Novel STAT3-JAK2 Fusions Identified in T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Daniel J. Landsburg, MD, Abramson Cancer Center
A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated With the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients With MYC-Altered Disease12:00 noon – 1:00 p.m. Lunch and Exhibits 1:00 p.m. – 1:30 p.m. Company Presentations (Cancelled) Free Time 1:30 p.m. – 3:15 p.m. Molecular Targeting (continued)
Chair:
Margaret A. Shipp, MD, Dana-Farber Cancer Institute
Speakers:
Margaret A. Shipp, MD, Dana-Farber Cancer Institute
Targetable Genetic Signatures in Lymphoid Malignancies
Louis Staudt, MD, PhD, National Cancer Institute, National Institutes of Health
Precision Therapy of Lymphoma via Genomics
Renier J. Brentjens, MD, PhD, Memorial Sloan Kettering Cancer Center
CAR T cell Therapy: CARs and Armored CARs
Oral Abstract Presenter:
James A. Heward, PhD, Barts Cancer Institute, Queen Mary University of London
KDM5 Inhibition Is a Novel Therapeutic Strategy for the Treatment of KMT2D Mutant Lymphomas3:15 p.m. – 3:45 p.m. Networking Coffee Break 3:45 p.m. – 5:15 p.m. Poster Presentations 5:15 p.m. – 6:45 p.m. Dinner (provided) 6:45 p.m. - 8:45 p.m. Molecular Pathogenesis of T-Cell Lymphoma
Chair:
Kojo S.J. Elenitoba-Johnson, MD, University of Pennsylvania
Speakers:
Laurence L. de Leval, MD, PhD, Lausanne University Hospital
Pathology and Genetic Lesions
Teresa Palomero, PhD, Columbia University
The Role of the RHOA G17V Mutation in the Pathogenesis of Angioimmunoblastic T-Cell Lymphoma (AITL)
Megan Lim, MD, PhD, University of Pennsylvania Perelman School of Medicine
Novel Insights Into Anaplastic Lymphoma Kinase-Mediated Pathogenetic Mechanisms in Anaplastic Large Cell Lymphoma
Oral Abstract Presenters:
Sayeef Mirza, MD, University of South Florida
Genomic Landscapes of Cutaneous T-Cell Lymphoma and Sezary Syndrome
Emmanuel Bachy, MD PhD, Lyon Sud Hospital
Whole-Genome Crispr/Cas9 Screens Uncover the C-Terminal Portion of the Long-Isoform of Cflip as Essential for Ptcl Survival -
Sunday - August 5
7:00 a.m. – 1:00 p.m. Registration 7:00 a.m. – 8:00 a.m. Breakfast and Exhibits 8:00 a.m. – 10:00 a.m. B-Cell Malignancies
Chair:
Laura Pasqualucci, MD, Columbia University
Speakers:
Bertrand Nadel, PhD, Centre D'Immunologie De Marseille-Luminy
Integrative Single-Cell Analysis: A New Prism to Decipher Follicular Lymphoma Heterogeneity
Ralf Kuppers, PhD, University of Duisburg - Essen
Hodgkin Lymphoma
Elias Campo, MD, PhD, University of Barcelona
Molecular Heterogeneity in Mantle Cell Lymphoma
Oral Abstract Presenters:
Elena Battistello, Swiss Federal Institute of Technology in Lausanne
Multimodal Inhibition of B Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma (DLBCL) Impacts DLBCL Evolution
Fen Zhu, University of Wisconsin School of Medicine and Public Health
Protein Arginine Methyltransferase 5 Is Upregulated by B Cell Antigen Receptor Signaling and Promotes the Survival of Diffuse Large B-Cell Lymphoma Cells10:00 a.m. – 10:20 a.m. Networking Coffee Break 10:20 a.m. – 12:20 p.m. Chronic Lymphocytic Leukemia
Chair:
Elias Campo, MD, PhD, University of Barcelona
Speakers:
Silvia Deaglio, MD, PhD, University of Turin
Microenvironmental Interactions in Chronic Lymphocytic Leukemia
Davide Rossi, MD, PhD, Oncology Institute of Southern Switzerland
Clinical Implications of Gene Mutations in Chronic Lymphocytic Leukemia
Francesco Forconi, MD, PhD, University of Southampton
B-Cell Receptor-Associated Kinase Inhibitors in Chronic Lymphocytic Leukemia
Oral Abstract Presenters:
Yong Li, PhD, Cleveland Clinic
Non-Proteolytic Polyubiquitination of Myd88 L265p in Class Switching Recombination and B-Cell Oncogenesis
Robert N. Booher, PhD, Curis, Inc.
Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination With Targeted Therapies in Diffuse Large B-Cell and Mantle Cell Lymphoma12:20 p.m. – 12:40 p.m. Closing Remarks From Program Co-Chairs